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Background: The purpose of this study was to determine the impact of adjuvant
radiotherapy (RT) in locoregionally advanced oral cavity cancer.
Methods: Data were extracted from the National Cancer Data Base, of which overall
survival (OS) is the only outcome variable available. The chi-square test and Cox
regression models were used.
Results: A total of 6654 patients were identified. The utilization of adjuvant RT has
increased over time. A propensity matched cohort included 3946 patients, exactly
one-half of whom received adjuvant RT. Independent predictors associated with
receipt of adjuvant RT included age, Charlson/Deyo comorbidity score, extracapsular
extension, surgical margins, and T and N classifications. On multivariable analysis,
adjuvant RT remained an independent prognosticator for OS.
Conclusion: Receipt of adjuvant RT is a prognostic factor associated with improved
OS, its utilization has increased over time, and it should be considered for clinically
suitable patients who have undergone resection for the disease.
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1 | INTRODUCTION
In 2017, Siegel et al1 estimated that there would be 32 670
new cases of oral cavity cancer in the United States and an
estimated 6650 deaths. Factors affecting prognosis in those
with oral cavity cancer include nodal involvement, extracap-
sular extension, surgical margins, tumor size, perineural inva-
sion, and tumor classification.2 In those with locoregionally
advanced oral cavity cancers, up-front resection is recom-
mended for those patients who present with resectable dis-
ease.3 These patients, however, are at significant risk for
locoregional recurrence after resection and are generally rec-
ommended for adjuvant therapy.4–9 Per the National Com-
prehensive Cancer Network guidelines, postoperative
adjuvant radiotherapy (RT) is the recommended treatment
for those presenting with risk features, including pT3 or pT4
primary, N2 or N3 nodal disease, or perineural invasion, and
adjuvant systemic therapy/RT is recommended for those
with extracapsular nodal extension or positive surgical
margins.3
Limited data exist regarding the specific impact of adju-
vant RT in those with locoregionally advanced disease partic-
ularly focused on primary tumors arising from the oral cavity.
The purpose of this hospital-based retrospective study on
6654 patients diagnosed with squamous cell carcinoma of the
oral cavity was to determine the prognostic factors for overall
survival (OS) and the utilization and impact of adjuvant RT
in those who have undergone resection for the disease.
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2 | MATERIALS AND METHODS
2.1 | Patient population
Data were extracted from the National Cancer Data Base
(NCDB), which include hospital registry data collected from
>1500 Commission on Cancer-accredited facilities repre-
senting 70% of newly diagnosed cancer cases annually in the
United States.10 It is a joint project of the Commission on
Cancer of the American College of Surgeons and the Ameri-
can Cancer Society. The data used in our investigation are
derived from a deidentified NCDB file. The American
College of Surgeons and the Commission on Cancer have
not verified and are not responsible for the analytic or statis-
tical methodology used, or the conclusions drawn from these
data by the investigators. The only outcome variable avail-
able in the NCDB is OS. This study was approved by the
institutional review board of Rush University Medical Cen-
ter, Chicago, IL, which waived the need for informed con-
sent for use of these deidentified data.
As seen in Figure 1, our study population consists of
6654 patients diagnosed with locoregionally advanced squa-
mous cell carcinoma of the oral cavity, including the anterior
two-thirds of the tongue, lip, gingiva, floor of mouth, hard
FIGURE 1 Flowchart describing the composition of the patient cohort
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palate, buccal mucosa, vestibule of mouth, retromolar tri-
gone, and oral cavity not otherwise specified (NOS; Interna-
tional Classification of Disease-0-3 histology code 8070/3-
8078/3) from 2004 to 2013. Classification groups III to IV,
including those with T3-4N0M0 and T1-4N1-3M0 disease
as defined by the American Joint Committee on Cancer 2017
classification system, were considered locoregionally
advanced.11 All study patients were 18 years or older and
underwent excision of the primary tumor with curative
intent. Patients receiving adjuvant RT received external
beam RT. Additional exclusion criteria included patients
with no record regarding T, N, or M classifications, extracap-
sular extension or surgical margin status, or receipt of adju-
vant RT or chemotherapy.
Comorbidities, as described by the Charlson/Deyo
comorbidity score, were defined by a weighted score derived
from the sum of the scores for each of the comorbid condi-
tions listed in the Charlson Comorbidity Score Mapping
Table.12,13 A score of 0 indicated no significant comorbid
conditions and higher scores indicated greater comorbidity
burden. Because of the small proportion of patients with a
Charlson Comorbidity score exceeding 2, the NCDB has
truncated the data to 0, 1, and 2 (>1). Insurance status was
identified as the patient’s primary insurance carrier at the
time of initial diagnosis and/or treatment. Categories, as sup-
plied by the NCDB for insurance status, include private,
uninsured, Medicaid, Medicare, and other governmental.
2.2 | Statistical analysis
All data analyses were performed using SPSS 23.0 (IBM,
Armonk, NY). Proportional distribution of demographic and
clinicopathologic factors, and treatment by receipt of adju-
vant RT were compared using the 2-tailed chi-square test.
The chi-square test of independence using Fisher’s exact test
determined whether there was an association between cate-
gorical variables. A cross-tabulation was performed, and the
P value (significance level of .05) was used to determine
whether the null hypothesis (no significant difference
between specified populations; any observed difference
being due to sampling error) could be rejected and whether a
statistical association between categorical variables existed.
The primary study end point was OS, which was defined as
time to death from the date of diagnosis of squamous cell
carcinoma of the oral cavity. Participating Commission on
Cancer-accredited registries report patient follow-ups to the
NCDB annually. The NCDB records the number of months
between the date of diagnosis and the date on which the
patient was last contacted or died. The NCDB does not
include cause of death information, so cause-specific survival
cannot be calculated. Factors significant on univariate OS
analysis were included in Cox regression multivariable anal-
ysis, which was used to compute hazard ratios (HRs) with
95% confidence intervals (CIs) to identify independent prog-
nostic factors for OS using a forward selection variable selec-
tion process. To adjust further for the effect of potential
confounding variables, a stepwise binary logistic regression
was used to determine predictors of adjuvant RT use in our
patient population. A propensity score model for the likeli-
hood of receiving adjuvant RT was developed, including the
covariates age at diagnosis, sex, race, Charlson/Deyo comor-
bidity score, insurance status, site of disease, extracapsular
extension status, surgical margin status, T classification, N
classification, tumor grade, and receipt of adjuvant chemo-
therapy. One-to-one propensity matching was then per-
formed with the fixed-caliper width set to 0.01, which has
demonstrated negligible relative bias (relative bias ranging
from -2% to 3%) and greater precision for estimating treat-
ment effects.14 These 2 cohorts (ie, adjuvant RT vs no adju-
vant RT) were compared using the log-rank test, and the HR
for OS was calculated using Cox regression. A landmark
analysis was also performed establishing a landmark time,
including only those patients who survived to this time point
and followed forward in time to evaluate whether OS is asso-
ciated with receipt of adjuvant RT. The 3-month landmark
was chosen a priori because this time point corresponds to
the usual interval at which a reclassification evaluation to
assess the effect of treatment would occur.3 Kaplan-Meier
methods were used to estimate survival probabilities. A 2-
sided P value < .05 was considered statistically significant.
3 | RESULTS
3.1 | Patient and treatment characteristics
A total of 6654 patients diagnosed with locoregionally
advanced squamous cell carcinoma of the oral cavity who
underwent primary tumor resection in 2004-2013 were iden-
tified (Table 1). The median age was 63 years (range 18-90
years). The population was predominately male, who were
white, had a Charlson/Deyo comorbidity score of 0, and car-
ried private insurance or Medicare. A total of 4287 patients
(64.4%) received adjuvant RT and 2367 (35.6%) did not.
Independent predictors associated with receipt of adju-
vant RT are shown in Table 2. These included younger age,
lower Charlson/Deyo comorbidity score, extracapsular exten-
sion, positive surgical margins, and T and N classifications
of disease. Over the study time period 2004-2013, the utiliza-
tion of adjuvant RT significantly increased from 43.1% in
2004 to 64.1% in 2013 (P 5 .019, chi-square test; Figure 2).
3.2 | Overall survival
The median time to follow-up was 22.2 months (range 1-126
months). Univariate analysis demonstrated that those who
received adjuvant RT (HR 0.756, 95% CI 0.692-0.825) were
SHIN ET AL. | 31936 SHIN ET AL.















Total 6654 2367 (35.6%) 4287 (64.4%) 1973 (50.0%) 1973 (50.0%)
Age, years
Median (range) 63 (18-90) < .001 .518
<63 3154 912 (28.9%) 2242 (71.1%) 809 (49.4%) 830 (50.6%)
63 3500 1455 (41.6%) 2045 (58.4%) 1164 (50.5%) 1143 (49.5%)
Sex < .001 .871
Male 4177 1406 (33.7%) 2771 (66.3%) 1190 (50.1%) 1184 (49.9%)
Female 2477 961 (38.8%) 1516 (61.2%) 783 (49.8%) 789 (50.2%)
Race .001 .761
White 5492 2007 (36.5%) 3485 (63.5%) 1693 (50.0%) 1690 (50.0%)
Black 557 173 (31.1%) 384 (68.9%) 148 (48.8%) 155 (51.2%)
Hispanic 267 84 (31.5%) 183 (68.5%) 78 (53.4%) 68 (46.6%)
Asian 209 55 (26.3%) 154 (73.7%) 54 (47.4%) 60 (52.6%)
Other 69 26 (37.7%) 43 (62.3%) . . . . . .
Unknown 60 22 (36.7%) 38 (63.3%) . . . . . .
Charlson/Deyo comorbidity score < .001 .280
0 4927 1654 (33.6%) 3273 (66.4%) 1469 (50.4%) 1448 (49.6%)
1 1322 504 (38.1%) 818 (61.9%) 384 (47.8%) 419 (52.2%)
2 405 209 (51.6%) 196 (48.4%) 120 (53.1%) 106 (46.9%)
Insurance status < .001 .468
Private 2244 668 (29.8%) 1576 (70.2%) 627 (49.9%) 630 (50.1%)
Uninsured 371 101 (27.2%) 270 (72.8%) 95 (44.8%) 117 (55.2%)
Medicaid 767 234 (30.5%) 533 (69.5%) 214 (50.5%) 210 (49.5%)
Medicare 3026 1277 (42.2%) 1749 (57.8%) 1037 (50.5%) 1016 (49.5%)
Other Governmental 127 43 (33.9%) 84 (66.1%) . . . . . .
Unknown 119 44 (37.0%) 75 (63.0%) . . . . . .
Site of disease < .001 .386
Anterior 2/3 tongue 704 198 (28.1%) 506 (71.9%) 176 (49.0%) 183 (51.0%)
Lip 194 77 (39.7%) 117 (60.3%) 71 (54.2%) 60 (45.8%)
Floor of mouth 2021 681 (33.7%) 1340 (66.3%) 572 (50.0%) 573 (50.0%)
Gingiva 1683 682 (40.5%) 1001 (59.5%) 532 (49.1%) 552 (50.9%)
Hard palate 193 72 (37.3%) 121 (62.7%) 64 (55.7%) 51 (44.3%)
Buccal mucosa 640 232 (36.3%) 408 (63.7%) 198 (51.4%) 187 (48.6%)
Vestibule of mouth 46 20 (43.5%) 26 (56.5%) 18 (62.1%) 11 (37.9%)
Retromolar trigone 717 225 (31.4%) 492 (68.6%) 196 (46.2%) 228 (53.8%)
Oral cavity, NOS 456 180 (39.5%) 276 (60.5%) 146 (53.3%) 128 (46.7%)
Extracapsular extension < .001 .320
No 4988 1966 (39.4%) 3022 (60.6%) 1642 (49.6%) 1666 (50.4%)
Yes 1666 401 (24.1%) 1265 (75.9%) 331 (51.9%) 307 (48.1%)
Positive surgical margins < .001 .964
No 5439 2021 (37.2%) 3418 (62.8%) 1681 (50.0%) 1683 (50.0%)
Yes 1215 346 (28.5%) 869 (71.5%) 292 (50.2%) 290 (49.8%)
(Continues)
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associated with significantly better OS than those who did
not (Table 3). Additionally, age at diagnosis, Charlson/Deyo
comorbidity score, insurance status, extracapsular extension,
surgical margins, T and N classifications of disease, and
tumor grade were statistically significant outcome factors.
On Cox regression multivariable analysis, receipt of adjuvant
RT (HR 0.640, 95% CI 0.582-0.704) remained an independ-
ent prognosticator for improved OS compared to nonreceipt
(Table 3). Additionally, older age at diagnosis (P < .001),
higher Charlson/Deyo comorbidity score (0 vs 2: HR 1.646,
P < .001), extracapsular extension (HR 1.469, P < .001),
positive surgical margins (HR 1.386, P < .001), higher T
classification (1 vs 2: HR 1.504, P < .001; 1 vs 3: HR
2.101, P < .001; 1 vs 4: HR 2.160, P < .001), and higher N
classification of disease (0 vs 1: HR 1.531, P < .001; 0 vs 2:
HR 2.318, P < .001; 0 vs 3: HR 2.662, P < .001) were sig-
nificant prognostic factors associated with worse OS.
3.3 | Sensitivity analyses
The propensity model was created, and the resultant matched
cohort included 3946 patients, exactly one half of whom
received adjuvant RT. There was an expected balance of
covariates between the 2 groups (Table 1). The HR from a
univariate Cox regression was 0.683 (P < .001), and from a
multivariable Cox regression it was 0.642 (P < .001; Table
4). Landmark analysis was used to evaluate the association
of adjuvant RT to OS. A 3-month landmark was chosen. For
patients diagnosed from 2004-2013 who survived at least 3
months, the median survivals for patients treated with and
without adjuvant RT were 51.3 months and 42.7 months,
respectively, and the 5-year OS probabilities were 47.9% ver-
sus 39.4% (P < .001; Figure 3).
3.4 | Subset analysis
In terms of patient characteristics, a statistically significant 5-
year OS benefit was observed in those 63 years (43.6% vs
31.9%, P < .001), whereas there was a trend toward signifi-
cance in those <63 years (53.5% vs 44.4%, P 5 .076; Table
5). Those with a Charlson/Deyo comorbidity score of 0 or 1
had an associated 5-year OS benefit with receipt of adjuvant
RT (0: 47.8% vs 38.0%, P < .001; 1: 54.6% vs 33.5%, P <
.001), whereas those with a Charlson/Deyo comorbidity
score of 2 did not have a demonstrated OS benefit (P 5
.635). A 5-year OS benefit was associated to adjuvant RT
regardless of extracapsular extension status (no: 50.5% vs
41.4%, P < .001; yes: 32.3% vs 15.0%, P < .001) or surgical
margin status (negative: 49.0% vs 40.0%, P < .001; positive:
39.9% vs 19.8%, P < .001). In those with no extracapsular
extension and negative surgical margins, no derived OS ben-
















T classification < .001 .209
1 619 216 (34.9%) 403 (65.1%) 188 (53.6%) 163 (46.4%)
2 705 193 (27.4%) 512 (72.6%) 178 (48.5%) 189 (51.5%)
3 447 174 (38.9%) 273 (61.1%) 146 (54.3%) 123 (45.7%)
4 4883 1784 (36.5%) 3099 (63.5%) 1461 (49.4%) 1498 (50.6%)
N classification < .001 .171
0 2814 1266 (45.0%) 1548 (55.0%) 1002 (49.1%) 1037 (50.9%)
1 1343 492 (36.6%) 851 (63.4%) 428 (50.5%) 419 (49.5%)
2 2450 596 (24.3%) 1854 (75.7%) 531 (50.9%) 513 (49.1%)
3 47 13 (27.7%) 34 (72.3%) 12 (75.0%) 4 (25.0%)
Grade < .001 .341
1 1079 440 (40.8%) 639 (59.2%) 359 (51.1%) 344 (48.9%)
2 4036 1430 (35.4%) 2606 (64.6%) 1196 (50.4%) 1177 (49.6%)
3 1273 398 (31.3%) 875 (68.7%) 338 (47.1%) 380 (52.9%)
Unknown 266 99 (37.2%) 167 (62.8%) 80 (52.6%) 72 (47.4%)
Adjuvant chemotherapy < .001 0.999
No 4405 2264 (51.4%) 2141 (48.6%) 1877 (50.0%) 1877 (50.0%)
Yes 2249 103 (4.6%) 2146 (95.4%) 96 (50.0%) 96 (50.0%)
Abbreviations: NOS, not otherwise specified; RT, radiotherapy.
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(30.9% vs 29.5%, P 5 .073). Those with higher T classifica-
tions were associated to a derived 5-year OS benefit with
adjuvant RT (T3: 43.6% vs 24.2%, P 5 .003; T4: 47.8% vs
38.2%, P < .001).
4 | DISCUSSION
We investigated the impact of adjuvant RT on OS in patients
with locoregionally advanced squamous cell carcinoma of
the oral cavity, and our study demonstrated important find-
ings. First, the utilization of adjuvant RT for these patients
with advanced disease has significantly increased over the
past decade. Next, those younger, or with less comorbidity
burden, extracapsular extension of disease, and positive sur-
gical margins, and higher T and N classifications of disease
are more likely to receive adjuvant RT. Conversely, those
who were older, with higher comorbidity burden, and with
less adverse features seen on final pathology status postresec-
tion are less likely to receive adjuvant RT. Finally, our data
suggest that adjuvant RT is significantly associated with
improved OS, which was maintained on multivariable and
landmark analyses among propensity-matched patients.
For those with locoregionally advanced squamous cell
carcinoma of the oral cavity, the National Comprehensive
Cancer Network recommends surgery and neck dissection
for resectable disease.3 Given the extent of disease, these
patients are at significant risk for local recurrence after resec-
tion. Unfavorable prognostic factors for local control in the
postoperative setting include close or positive surgical mar-
gins, extracapsular extension, tumor depth, perineural inva-
sion, and nodal metastasis, and patients with combinations of
these adverse pathologic features have been associated with
significantly decreased OS in addition to decreased locore-
gional control rates.15,16 A 35-year single institutional study
on 226 patients with primary oral cavity cancer treated with
adjuvant RT found that these factors were significant prog-
nosticators for locoregional control on multivariable
analysis.17
Positive surgical margins and extracapsular extension in
particular are 2 unfavorable high-risk factors,18–20 and our
subset analyses, including propensity-matched patients, sug-
gest that a significant absolute benefit for adjuvant RT was
TABLE 2 Independent predictors associated with adjuvant
radiotherapy
Variables HR 95% CI P value
Age, years
<63 Reference
63 0.721 0.623-0.834 < .001
Sex
Man Reference
Woman 0.895 0.800-1.002 .053
Race
Black Reference
White 0.866 0.706-1.062 .166
Hispanic 1.036 0.743-1.445 .835
Asian 1.267 0.868-1.849 .221
Charlson/Deyo comorbidity score
0 Reference
1 0.844 0.738-0.965 .013
2 0.516 0.415-0.641 <.001
Insurance status
Private Reference
Uninsured 1.016 0.785-1.314 .905
Medicaid 0.832 0.689-1.006 .057
Medicare 0.762 0.657-0.885 <.001
Site
Anterior 2/3 tongue Reference
Lip 0.680 0.478-0.968 .032
Floor of mouth 0.839 0.680-1.034 .099
Gingiva 0.819 0.657-1.020 .075
Hard palate 0.745 0.518-1.073 .114
Buccal mucosa 0.797 0.622-1.021 .073
Vestibule of mouth 0.577 0.304-1.097 .093
Retromolar trigone 1.010 0.785-1.298 .941
Oral cavity, NOS 0.713 0.541-0.941 .017
Extracapsular extension
No Reference
Yes 1.303 1.112-1.527 .001
Positive surgical margins
No Reference
Yes 1.388 1.199-1.607 <.001
T classification
1 Reference
2 1.295 1.012-1.658 .040
3 1.065 0.804-1.411 .661
4 1.254 1.021-1.540 .031
N classification
0 Reference
1 1.299 1.104-1.528 .002
2 2.004 1.710-2.349 < .001
3 1.474 0.739-2.941 .271
(Continues)
TABLE 2 (Continued)
Variables HR 95% CI P value
Grade
1 Reference
2 1.043 0.899-1.210 .581
3 1.136 0.944-1.366 .177
Unknown 0.956 0.708-1.290 .767
Abbreviations: CI, confidence interval; HR, hazard ratio.
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FIGURE 2 Utilization of adjuvant radiotherapy over the time period 2004-2013 (P5 .019, chi-square test)
TABLE 3 Cox regression univariate and multivariable analysis for overall survival for all patients
Univariate Multivariable
Variables HR 95% CI P value HR 95% CI P value
Age at diagnosisa 1.021 1.017-1.025 < .001 1.021 1.016-1.026 < .001
Sex
Male Reference ND
Female 1.033 0.919-1.095 .948
Race
Black Reference ND
White 0.973 0.836-1.132 .973
Hispanic 0.794 0.605-1.043 .794
Asian 0.832 0.611-1.131 .832
Charlson/Deyo comorbidity score
0 Reference Reference
1 1.182 1.063-1.314 .002 1.094 0.982-1.219 .102
2 1.870 1.602-2.184 < .001 1.646 1.404-1.930 < .001
Insurance status
Private Reference Reference
Uninsured 1.094 0.887-1.350 .401 1.104 0.893-1.364 .361
Medicaid 1.419 1.225-1.644 < .001 1.429 1.230-1.659 < .001
Medicare 1.650 1.492-1.824 < .001 1.263 1.118-1.427 < .001
Site
Anterior 2/3 tongue Reference Reference
Lip 0.704 0.520-0.951 .022 0.604 0.443- 0.824 .001
Floor of mouth 1.006 0.861-1.175 .940 0.850 0.721-1.002 .053
Gingiva 0.861 0.731-1.012 .070 0.716 0.599-0.856 < .001
Hard palate 1.275 0.971-1.674 .081 0.893 0.674-1.185 .433
Buccal mucosa 1.189 0.984-1.438 .073 1.037 0.852-1.262 .718
Vestibule of mouth 1.268 0.773-2.079 .347 0.856 0.521-1.407 .540
Retromolar trigone 0.967 0.803-1.165 .727 0.771 0.633-0.939 .010
(Continues)
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derived in patients with either of these high-risk features.
The presence of T3 to T4 disease without involved margins
or extracapsular extension was also associated with a signifi-
cant OS benefit when adjuvant RT was received. These
results strongly argue for the importance of adjuvant RT for
patients with adverse pathologic features. A phase III
randomized trial conducted in India on 900 patients with
locally advanced and resectable squamous cell carcinoma of
the oral cavity found 5-year locoregional control to be
58.2%-65.1% for those receiving adjuvant RT or chemora-
diotherapy,4 of whom 90% had T3 to T4 tumors, and 48%
had N2 to N3 disease. Very few patients had positive mar-
gins; although 54.7% had extracapsular extension and 329
(36.5%) had multiple nodal involvements. Additionally, our
data demonstrated that receipt of adjuvant RT in patients
with locoregionally advanced disease with moderately or
poorly differentiated tumors are also associated with an OS
benefit, suggesting that tumor grade should be given consid-
eration as an adverse risk feature to be used on multivariable
models in this cohort. This result is consistent with a Surveil-
lance, Epidemiology, and End Results study published by
Thomas et al,21 which demonstrated a strong association
between tumor grade and disease-specific survival for
patients with classifications I to II with squamous cell carci-
noma of the oral cavity and noted an adjusted risk of death
2.7 times greater if the tumor was poorly differentiated or
undifferentiated compared to well-differentiated tumors.
In contrast, there may be those who may not derive an
OS benefit with the addition of adjuvant RT. In a random-
ized trial on patients with advanced head and neck squamous
cell carcinoma, 213 patients were prospectively studied with
15% having no adverse pathologic factors and receiving no
TABLE 3 (Continued)
Univariate Multivariable
Variables HR 95% CI P value HR 95% CI P value
Oral cavity, NOS 1.011 0.817-1.252 .917 0.813 0.649-1.019 .073
Extracapsular extension
No Reference Reference
Yes 1.952 1.782-2.138 < .001 1.469 1.312-1.644 < .001
Positive surgical margins
No Reference Reference
Yes 1.261 1.138-1.396 < .001 1.386 1.247-1.541 < .001
T classification
1 Reference Reference
2 1.556 1.259-1.923 < .001 1.504 1.213-1.864 < .001
3 1.685 1.336-2.125 < .001 2.101 1.652-2.673 < .001
4 1.580 1.329-1.879 < .001 2.160 1.797-2.597 < .001
N classification
0 Reference Reference
1 1.252 1.105-1.417 < .001 1.531 1.332-1.760 < .001
2 2.121 1.926-2.335 < .001 2.318 2.046-2.627 < .001
3 2.711 1.738-4.229 < .001 2.662 1.651-4.295 < .001
Grade
1 Reference Reference
2 1.094 0.968-1.236 .152 0.997 0.878-1.132 .964
3 1.370 1.188-1.578 < .001 1.110 0.957-1.287 .168
Unknown 1.114 0.882-1.407 .366 1.062 0.834-1.350 .627
Adjuvant RT
No Reference Reference
Yes 0.756 0.692-0.825 < .001 0.640 0.582-0.704 < .001
Adjuvant chemotherapy
No Reference ND
Yes 1.035 0.947-1.132 .444
Abbreviations: CI, confidence interval; HR, hazard ratio; ND, not determined; NOS, not otherwise specified; RT, radiotherapy.
aAnalyzed as a continuous variable.
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TABLE 4 Cox regression univariate and multivariable analysis for overall survival for propensity-matched patients
Univariate Multivariable
Variable HR 95% CI P value HR 95% CI P value
Age at diagnosisa 1.025 1.020-1.030 < .001 1.024 1.018-1.031 < .001
Sex
Male Reference ND
Female 1.017 0.908-1.138 .773
Race
Black Reference
White 0.921 0.752-1.128 .427 0.914 0.741-1.127 .400
Hispanic 0.656 0.445-0.968 .033 0.665 0.449-0.984 .042
Asian 0.797 0.530-1.197 .274 0.896 0.591-1.356 .602
Charlson/Deyo comorbidity score
0 Reference Reference
1 1.266 1.105-1.449 .001 1.186 1.035-1.360 .014
2 1.964 1.603-2.406 < .001 1.776 1.447-2.181 < .001
Insurance status
Private Reference Reference
Uninsured 1.170 0.875-1.564 .290 1.192 0.889-1.600 .241
Medicaid 1.603 1.309-1.963 < .001 1.560 1.265-1.925 < .001
Medicare 1.828 1.597-2.093 < .001 1.318 1.120-1.550 .001
Site
Anterior 2/3 tongue Reference Reference
Lip 0.644 0.435-0.955 .029 0.570 0.383-0.848 .006
Floor of mouth 1.054 0.846-1.314 .636 0.992 0.788-1.248 .946
Gingiva 0.792 0.632-0.993 .044 0.746 0.583-0.953 .019
Hard palate 1.322 0.924-1.889 .126 0.921 0.637-1.330 .660
Buccal mucosa 1.143 0.878-1.486 .321 1.072 0.819-1.403 .612
Vestibule of mouth 1.630 0.914-2.905 .098 0.952 0.532-1.705 .870
Retromolar trigone 1.014 0.787-1.307 .912 0.884 0.678-1.151 .359
Oral cavity, NOS 0.990 0.739-1.325 .944 0.885 0.654-1.197 .427
Extracapsular extension
No Reference Reference
Yes 2.703 2.370-3.083 < .001 1.745 1.490-2.044 < .001
Positive surgical margins
No Reference Reference
Yes 1.654 1.438-1.903 < .001 1.425 1.236-1.644 < .001
T classification
1 Reference Reference
2 1.494 1.131-1.972 .005 1.356 1.026-1.792 .033
3 1.590 1.183-2.139 .002 2.018 1.480- 2.750 < .001
4 1.304 1.043-1.630 .020 1.924 1.514-2.444 < .001
N classification
0 Reference Reference
1 1.409 1.210-1.639 < .001 1.578 1.329-1.873 < .001
2 2.785 2.453-3.162 < .001 2.341 1.997-2.745 < .001
3 3.947 1.764-8.830 .001 2.481 1.091-5.645 .030
(Continues)
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adjuvant therapy, and had a 5-year locoregional control rate
of 83%.22 In the absence of extracapsular extension or posi-
tive surgical margins, our data demonstrated that adjuvant
RT was not associated with an OS benefit in patients with
N2 disease who underwent primary resection and lymph
node dissection in our propensity-matched analysis. Addi-
tionally, those with less aggressive disease, including those
with T1 to T2 and grade 1 disease, respectively, were not
associated with an OS benefit upon receipt of adjuvant RT.
These findings suggest that certain patient subsets with
locoregionally advanced disease undergoing primary resec-
tion with lymph node dissection and ultimately more favor-
able final pathologic findings have a good prognosis with
surgery alone. In terms of patient characteristics, no statisti-
cally significant OS benefit associated with adjuvant RT was
observed in those with a Charlson/Deyo comorbidity score
of 2. Reasons for this are likely multifactorial in etiology but
previous studies related to the prognostic impact of comor-
bidity and cancer have found that although comorbidity does
not seem to be associated with more aggressive types of can-
cer or other differences in tumor biology, postoperative com-
plications, and mortality are higher and the chance of
completing a course of cancer treatment is lower for those
with great comorbidity burden.23
Our data suggest that the use of adjuvant RT has grown
over the past decade, and reasons for this can only be
hypothesized given the limitations of the NCDB but are also
likely multifactorial in etiology. The use of intensity-
modulated radiotherapy for head and neck cancer, which
offers improvements in side effect profile and quality of life
when compared with conventional RT techniques,24 has sig-
nificantly increased with 1.3% of patients receiving it in
2000 compared to 46.1% in 2005 (P < .001) as demonstrated
in a Surveillance, Epidemiology, and End Results-Medicare
analysis on 5487 patients, although significant geographic
variation was noted.25 We did not report intensity-modulated
RT use as a variable in our study given that the NCDB and
its radiation technique options(eg, conventional vs 3D con-
formal vs intensity-modulated RT) are not mutually exclu-
sive. Insurance status has been associated with disparities in
treatment delivery for head and neck cancers with those
patients who are insured more likely to receive definitive
treatment than those who are uninsured.26 The Affordable
Care Act was introduced in 2010 and launched major regula-
tory changes of the U.S. healthcare system with the goal to
increase patient access to health insurance coverage.27 In
TABLE 4 (Continued)
Univariate Multivariable
Variable HR 95% CI P value HR 95% CI P value
Grade
1 Reference Reference
2 1.064 0.910-1.243 .436 0.969 0.827-1.136 .698
3 1.395 1.162-1.674 < .001 1.086 0.899-1.313 .392
Unknown 1.079 0.796-1.464 .624 0.997 0.733-1.356 .984
Adjuvant RT
No Reference Reference
Yes 0.683 0.611-0.764 < .001 0.642 0.573-0.719 < .001
Adjuvant chemotherapy
No Reference ND
Yes 1.208 0.942-1.548 .136
Abbreviations: CI, confidence interval; HR, hazard ratio; ND, not determined; NOS, not otherwise specified; RT, radiotherapy.
aAnalyzed as a continuous variable.
FIGURE 3 Kaplan-Meier overall survival by landmark analysis of
propensity-matched patients alive at 3 months (P< .001)
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2013, 13.3% of the entire U.S. population was found to be
uninsured for the entire year, and the uninsured rate had
decreased to 10.4% for the calendar year 2014.28 The
observed increase in adjuvant RT utilization may also be
reflective of the NCDB and the possibility of increased cap-
ture of RT data by Commission on Cancer institutions over
time, whereas the tumor registrar might be more likely to
have access to RT records. Linking of hospital and radiation
oncology electronic health records and implementation of
electronic data capture systems to access population research
databases prospectively and better facilitate outcomes report-
ing have been developed.29,30 Further epidemiological
TABLE 5 Kaplan-Meier 5-year overall survival stratified by patient and tumor characteristics for propensity-matched patients
Variables No adjuvant RT Adjuvant RT Log-rank P value
Overall 37.0% (6 2.4) 47.7% (6 2.2) < .001
Age, years
<63 44.4% (6 4.3) 53.5% (6 3.4) .076
63 31.9% (6 2.7) 43.6% (6 3.0) < .001
Charlson/Deyo comorbidity score
0 38.0% (6 3.0) 47.8% (6 2.7) < .001
1 33.5% (6 4.1) 54.6% (6 3.5) < .001
2 30.2% (6 6.0) 26.5% (6 7.7) .635
Extracapsular extension
No 41.4% (6 2.6) 50.5% (6 2.5) < .001
Positive margins
No 44.1% (6 2.9) 51.6% (6 2.7) < .001
N2 29.5% (6 7.3) 30.9% (6 6.7) .073
T3-4 44.2% (6 3.0) 51.2% (6 2.9) < .001
Yes 24.6% (6 5.9) 43.4% (6 6.0) .001
Yes 15.0% (6 3.0) 32.3% (6 4.2) < .001
Positive surgical margins
No 40.0% (6 2.6) 49.0% (6 2.5) < .001
Extracapsular extension
No 44.1% (6 2.9) 51.6% (6 2.7) < .001
N2 29.5% (6 7.3) 30.9% (6 6.7) .073
T3-4 44.2% (6 3.0) 51.2% (6 2.9) < .001
Yes 16.6% (6 3.6) 33.9% (6 4.9) < .001
Yes 19.8% (6 4.8) 39.9% (6 4.9) < .001
T classification
1 57.8% (6 5.1) 50.8% (6 10.3) .487
2 24.0% (6 10.5) 45.1% (6 6.3) .073
3 24.2% (6 8.1) 43.6% (6 10.0) .003
4 38.2% (6 2.6) 47.8% (6 2.5) < .001
N classification
0 47.0% (6 3.2) 58.8% (6 2.7) < .001
1 32.4% (6 7.2) 43.6% (6 6.9) .003
2 18.9% (6 4.1) 25.3% (6 4.4) < .001
3 . . . . . . . . .
Grade
1 46.8% (6 5.8) 44.9% (6 5.2) .161
2 38.1% (6 3.0) 49.7% (6 2.8) < .001
3 31.3% (6 3.9) 46.0% (6 5.6) < .001
Unknown 27.0% (6 10.2) 45.8% (6 9.0) .703
Abbreviation: RT, radiotherapy.
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studies on the utilization of RT for patients with head and
neck cancers are warranted.
Our study represents a large comprehensive analysis
investigating prognostic factors and the impact of adjuvant
RT on patients with resected locoregionally advanced squa-
mous cell carcinoma of the oral cavity. The major strength in
our investigation lies in the large patient numbers, which
allowed for statistical analyses powered for detection of dif-
ferences in OS. The NCDB is a highly standardized hospital-
based cancer registry, undergoing a series of quality assur-
ance measures and checks while collecting information on
70% of patients with newly diagnosed cancer annually.10
However, intrinsic limitations to any large database retro-
spective analysis must also be considered with lack of certain
data variables possibly leading to confounding impact of
important factors that could not be investigated in our study.
Patients from the NCDB are only reported by Commission
on Cancer-accredited facilities, thus possibly introducing
hospital-selection bias. In addition, the NCDB does not have
records on preoperative and postoperative imaging, patient
adherence to treatment recommendations, disease recurrence,
or any subsequent salvage therapy. There is limited informa-
tion on some intermediate-risk head and neck cancer fea-
tures, such as perineural invasion, lymphovascular space
invasion, and depth of invasion. Number of involved nodes
and nodal stations involved were not specifically analyzed in
our study as well. Additionally, risk factors, including
tobacco and alcohol use, which are among the strongest dis-
ease risk factors for squamous cell carcinoma of the oral cav-
ity, are not specifically recorded.31 Thus, we cannot evaluate
the extent to which all of these factors may contribute to
patient outcome, a limitation that can present a greater risk of
unmeasured confounding. Another significant limitation of
this study is the short median follow-up. A shorter median
follow-up may lead to analyses biased toward patients with
shorter follow-up. The interpretation of survival analyses
depends on the completeness of patient follow-up, and suffi-
cient follow-up to capture an adequate number of events is
necessary to ensure sufficient statistical power for outcome-
based data analyses.32,33 However, the role of median
follow-up in describing the stability and validity of the
Kaplan-Meier curve estimates is also debatable, as some
argue that Kaplan-Meier curves adjust for variable lengths of
follow-up and provide an unbiased estimate of the true popu-
lation survival curve.34 Regardless, median follow-up is a
term that continues to be used in outcome-based cancer
research, and our short median follow-up warrants the need
for future studies with more mature data and longer median
follow-up. Finally, the NCDB does not collect cancer-
specific survival information, which may produce different
results from that of all-cause deaths.
Our findings from this hospital-based retrospective
propensity-score matched analysis suggest that receipt of
adjuvant RT is associated with significantly improved OS in
those with locoregionally advanced squamous cell carcinoma
of the oral cavity, and that it should strongly be considered for
all clinically suitable patients who have undergone resection for
the disease. As techniques for RT delivery continue to be opti-
mized and its utilization increased, further studies are warranted
to continue to investigate prospectively which specific sub-
groups of patients truly benefit from treatment so that disease
control and outcomes can be further improved, while minimiz-
ing unnecessary treatment toxicity and maintaining quality of
life.
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